JAGUAR HEALTH, INC. Cost of Revenue
JAGUAR HEALTH, INC. (JAGX) reported Cost of Revenue of $97.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-07.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-19
- JAGUAR HEALTH, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $0.00.
- JAGUAR HEALTH, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $0.00.
- JAGUAR HEALTH, INC. cost of goods and services sold for the quarter ending 2025-06-30 was $97.00K.
- JAGUAR HEALTH, INC. cost of goods and services sold for fiscal 2025 was $97.00K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $0.00 derived: sum of 2 quarters · filed 2026-04-07 | $97.00K derived: sum of 3 quarters · filed 2026-08-19 | $97.00K 10-K · filed 2026-04-07 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $97.00K derived: sum of 2 quarters · filed 2026-08-19 | $97.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $97.00K 10-Q · filed 2026-08-19 | $97.00K 10-Q · filed 2026-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |